Literature DB >> 25048629

Emerging approaches to target tumor metabolism.

Sarah J Ross1, Susan E Critchlow2.   

Abstract

Therapeutic exploitation of the next generation of drugs targeting the genetic basis of cancer will require an understanding of how cancer genes regulate tumor biology. Reprogramming of tumor metabolism has been linked with activation of oncogenes and inactivation of tumor suppressors. Well established and emerging cancer genes such as MYC, IDH1/2 and KEAP1 regulate tumor metabolism opening up opportunities to evaluate metabolic pathway inhibition as a therapeutic strategy in these tumors.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25048629     DOI: 10.1016/j.coph.2014.07.001

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  10 in total

Review 1.  Autophagy and Tumor Metabolism.

Authors:  Alec C Kimmelman; Eileen White
Journal:  Cell Metab       Date:  2017-05-02       Impact factor: 27.287

2.  MYC Is a Crucial Mediator of TGFβ-Induced Invasion in Basal Breast Cancer.

Authors:  Magdalena A Cichon; Megan E Moruzzi; Tiziana A Shqau; Erin Miller; Christine Mehner; Stephen P Ethier; John A Copland; Evette S Radisky; Derek C Radisky
Journal:  Cancer Res       Date:  2016-04-13       Impact factor: 12.701

3.  Effects of a monocarboxylate transport 1 inhibitor, AZD3965, on retinal and visual function in the rat.

Authors:  Annette E Allen; Elizabeth A Martin; Katherine Greenwood; Claire Grant; Peter Vince; Robert J Lucas; William S Redfern
Journal:  Br J Pharmacol       Date:  2020-09-13       Impact factor: 8.739

4.  Bioinformatics analysis of the serine and glycine pathway in cancer cells.

Authors:  Alexey Antonov; Massimiliano Agostini; Maria Morello; Marilena Minieri; Gerry Melino; Ivano Amelio
Journal:  Oncotarget       Date:  2014-11-30

Review 5.  The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis.

Authors:  Ran Xu; Ziyi Ji; Chen Xu; Jing Zhu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

Review 6.  A Deep Insight Into Regulatory T Cell Metabolism in Renal Disease: Facts and Perspectives.

Authors:  Zhongyu Han; Kuai Ma; Hongxia Tao; Hongli Liu; Jiong Zhang; Xiyalatu Sai; Yunlong Li; Mingxuan Chi; Qing Nian; Linjiang Song; Chi Liu
Journal:  Front Immunol       Date:  2022-02-17       Impact factor: 7.561

Review 7.  The emerging nexus of active DNA demethylation and mitochondrial oxidative metabolism in post-mitotic neurons.

Authors:  Huan Meng; Guiquan Chen; Hui-Ming Gao; Xiaoyu Song; Yun Shi; Liu Cao
Journal:  Int J Mol Sci       Date:  2014-12-05       Impact factor: 5.923

8.  Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism.

Authors:  Harri M Itkonen; Saurabh S Gorad; Damien Y Duveau; Sara E S Martin; Anna Barkovskaya; Tone F Bathen; Siver A Moestue; Ian G Mills
Journal:  Oncotarget       Date:  2016-03-15

9.  Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription.

Authors:  Jian Kang; Eric P Kusnadi; Allison J Ogden; Rodney J Hicks; Lukas Bammert; Ulrike Kutay; Sandy Hung; Elaine Sanij; Ross D Hannan; Katherine M Hannan; Richard B Pearson
Journal:  Oncotarget       Date:  2016-08-02

10.  Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.

Authors:  Nicola J Curtis; Lorraine Mooney; Lorna Hopcroft; Filippos Michopoulos; Nichola Whalley; Haihong Zhong; Clare Murray; Armelle Logie; Mitchell Revill; Kate F Byth; Amanda D Benjamin; Mike A Firth; Stephen Green; Paul D Smith; Susan E Critchlow
Journal:  Oncotarget       Date:  2017-05-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.